Compare GSK plc (GSK) vs Zscaler Inc (ZS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
GSK plc vs Zscaler Inc — how do they compare? GSK plc trades at $52.61 (market cap $101.34B), while Zscaler Inc trades at $146.38 (market cap $23.96B). The key difference: GSK plc is far larger — about 4.2× Zscaler Inc's market cap, and GSK plc pays a 3.49% dividend while Zscaler Inc pays none. Which is the better fit depends on your goals.
| GSK | ZS | |
|---|---|---|
Market Cap | $101.34B | $23.96B |
Sector | Health | Technology |
52-Week High | $61.18 | $336.27 |
52-Week Low | $36.20 | $118.05 |
Enterprise Value | $121.95B | $22.29B |
Dividend Yield | 3.49% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
GSK trades at $52.64, up 2.7% on the day, with a bearish technical signal despite recent earnings beats. The company reported Q1 2026 EPS of $1.24, beating estimates of $1.16, and maintains strong profitability with a 17.78% net income margin. Positive clinical trial results for Jemperli in rectal cancer and FDA approval for Utebzi highlight pipeline strength, while a pending acquisition of Nuvalent, Inc. signals strategic expansion.
GSK offers value with a P/E of 13.71 and stable cash flows, but faces risks from clinical setbacks, as seen in the terminated Alector partnership. Analyst sentiment is mixed with 31% buy ratings, reflecting cautious optimism amid competitive and regulatory pressures. The stock's outlook hinges on execution of growth initiatives and pipeline developments.
Zscaler (ZS) trades at $146.75, down 3.51% on the day, with a bullish technical outlook supported by moving averages and key support at $145. The company shows strong revenue growth, reaching $2.67B in 2025, but remains unprofitable with a net margin of -2.44%. Recent quarters have consistently beaten EPS expectations, and analyst sentiment is overwhelmingly positive with 79% buy ratings.
ZS offers growth potential in cybersecurity with Zero Trust adoption and AI integration, but faces risks from profitability challenges, rising infrastructure costs, and legal investigations. The consensus price target of $192.64 implies significant upside, though investors must weigh strong demand against margin pressures and competitive threats.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About GSK plc
In the pharmaceutical industry, GSK ranks as one of the largest firms by total sales. The company wields its might across several therapeutic classes, including respiratory, cancer, and antiviral, as well as vaccines. GSK uses joint ventures to gain additional scale in certain markets like HIV.
Read more on GSK →About Zscaler Inc
Zscaler is a security-as-a-service firm that offers its customers cloud-delivered solutions for protecting user devices and data. The firm leverages its position in 150 colocation data centers to deliver traditionally appliance-based security functionality, such as firewalls and sandboxes, as a completely cloud-native platform. The firm focuses on large enterprise customers and offers two primary product suites: Zscaler Internet Access, which securely connects users to externally managed application and websites (such as Salesforce and Google), and Zscaler Private Access, which securely connects users to internally managed applications. Both product suites encompass a broad gamut of capabilities situated across the traditional security stack.
Read more on ZS →
